Answers are grounded in this paper and cite their sources.
We discuss the case of a 74-year old male patient with mantle cell lymphoma, who faced severe CMV infection after the fifth cycle of first-line chemo-immunotherapy with a dose-reduced bendamustine and rituximab regimen.
No takes yet. Share an insight, caveat, or question.
Magliano et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: